[{"orgOrder":0,"company":"Mangalam Drugs & Organics Ltd","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"Pyronaridine Tetraphosphate","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mangalam Drugs & Organics Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mangalam Drugs & Organics Ltd \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"15","companyTruncated":"Mangalam Drugs & Organics Ltd \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"University Hospital T\u00fcbingen","sponsor":"Sanaria | University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyronaridine Tetraphosphate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University Hospital T\u00fcbingen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital T\u00fcbingen \/ Sanaria | University of Oxford","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital T\u00fcbingen \/ Sanaria | University of Oxford"},{"orgOrder":0,"company":"Medicines for Malaria Venture","sponsor":"Richmond Pharmacology | PharmaKinetic","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pyronaridine Tetraphosphate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Medicines for Malaria Venture","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicines for Malaria Venture \/ Richmond Pharmacology | PharmaKinetic","highestDevelopmentStatusID":"6","companyTruncated":"Medicines for Malaria Venture \/ Richmond Pharmacology | PharmaKinetic"},{"orgOrder":0,"company":"Armaceutica, Inc.","sponsor":"Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyronaridine Tetraphosphate","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Armaceutica, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Armaceutica, Inc. \/ Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal","highestDevelopmentStatusID":"8","companyTruncated":"Armaceutica, Inc. \/ Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal"}]

Find Clinical Drug Pipeline Developments & Deals for Pyronaridine Tetraphosphate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : The grant will support research and development efforts aimed at improving the technology and efficiency of pyronaridine production for pyronaridine-artesunate combination therapy, Pyramax.

                          Product Name : Pyramax

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          August 27, 2024

                          Lead Product(s) : Pyronaridine Tetraphosphate,Artesunate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Medicines for Malaria Venture

                          Deal Size : $0.2 million

                          Deal Type : Funding

                          blank

                          02

                          University Hospital Tübingen

                          Country arrow
                          BioJapan
                          Not Confirmed

                          University Hospital Tübingen

                          Country arrow
                          BioJapan
                          Not Confirmed

                          Details : Pyronaridine Tetraphosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Malaria.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 01, 2022

                          Lead Product(s) : Pyronaridine Tetraphosphate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Sanaria | University of Oxford

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Armaceutica, Inc.

                          Country arrow
                          BioJapan
                          Not Confirmed

                          Armaceutica, Inc.

                          Country arrow
                          BioJapan
                          Not Confirmed

                          Lead Product(s) : Pyronaridine Tetraphosphate

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Pyronaridine Tetraphosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 22, 2022

                          Lead Product(s) : Pyronaridine Tetraphosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Medicines for Malaria Venture

                          Country arrow
                          BioJapan
                          Not Confirmed

                          Medicines for Malaria Venture

                          Country arrow
                          BioJapan
                          Not Confirmed

                          Details : Pyronaridine Tetraphosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 16, 2021

                          Lead Product(s) : Pyronaridine Tetraphosphate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Richmond Pharmacology | PharmaKinetic

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank